EVOID-AS (NCT05143177)

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient’s Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 3 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient’s Calcific Aortic Valve Disease with Mild to Moderate Aortic Stenosis (EVOID-AS).

PI: Dr. Alexander Postalian

SPONSOR: REDNIVA

ACTIVE ENROLLING   SIGN UP

Eligibility Requirements:

1. Male or female adult ≥ 35 years of age at time of screening

2. Subject has calcific aortic valve disease with mild to moderate aortic stenosis as defined by:

• Doppler echocardiography results: Aortic Valve mean pressure gradient between 10-30 mmHg and Aortic Valve Area ≥ 1.2 and ≤ 2.0 cm2 on TTE
• Cardiac Computed Tomography (CT) test results: aortic valve calcium score (Agatston score) ≥ 200 AU at baseline cardiac CT

EVOID STUDY PARTICIPATION FLYER